Elite Pharmaceuticals Inc Financials
Elite Pharmaceuticals Inc (ELTP) reported $148.9M in revenue for fiscal year 2026, up 77.1% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Elite’s growth engine is now showing strong operating leverage, with sales scaling far faster than overhead and reinvestment needs.
In FY2026, net income of$44.9M turned into only$23.7M of operating cash flow, because rapid growth pulled more cash into accounts receivable rather than straight into the bank. That is still a meaningful upgrade from FY2024, when reported profit was$20.1M but operating cash flow was-$3.2M , so the business now looks more cash-backed even though collections are absorbing part of the surge.
The margin step-up is not just a gross-margin story: operating margin reached
Capital intensity is unusually light for the current scale, with free cash flow of
Financial Health Signals
Elite Pharmaceuticals Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Elite Pharmaceuticals Inc scores 6.98, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($307.0M) relative to total liabilities ($39.4M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Elite Pharmaceuticals Inc passes 6 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Elite Pharmaceuticals Inc generates $0.53 in operating cash flow ($23.7M OCF vs $44.9M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
Elite Pharmaceuticals Inc earns $441.03 in operating income for every $1 of interest expense ($49.1M vs $111K). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Elite Pharmaceuticals Inc generated $148.9M in revenue in fiscal year 2026. This represents an increase of 77.1% from the prior year.
Elite Pharmaceuticals Inc's EBITDA was $50.2M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 141.0% from the prior year.
Elite Pharmaceuticals Inc reported $44.9M in net income in fiscal year 2026. This represents an increase of 1140.0% from the prior year.
Elite Pharmaceuticals Inc earned $0.03 per diluted share (EPS) in fiscal year 2026.
Cash & Balance Sheet
Elite Pharmaceuticals Inc generated $22.8M in free cash flow in fiscal year 2026, representing cash available after capex. This represents an increase of 291.4% from the prior year.
Elite Pharmaceuticals Inc held $30.3M in cash as of fiscal year 2026; long-term debt is not reported for that period.
Not reported for fiscal year 2026.
Margins & Returns
Elite Pharmaceuticals Inc's gross margin was 50.4% in fiscal year 2026, indicating the percentage of revenue retained after direct costs. This is up 2.7 percentage points from the prior year.
Elite Pharmaceuticals Inc's operating margin was 33.0% in fiscal year 2026, reflecting core business profitability. This is up 9.7 percentage points from the prior year.
Elite Pharmaceuticals Inc's net profit margin was 30.1% in fiscal year 2026, showing the share of revenue converted to profit. This is up 35.3 percentage points from the prior year.
Elite Pharmaceuticals Inc's ROE was 45.4% in fiscal year 2026, measuring profit generated per dollar of shareholder equity. This is up 53.4 percentage points from the prior year.
Capital Allocation
Elite Pharmaceuticals Inc invested $5.7M in research and development in fiscal year 2026. This represents a decrease of 27.9% from the prior year.
Elite Pharmaceuticals Inc invested $926K in capex in fiscal year 2026, funding long-term assets and infrastructure. This represents a decrease of 43.0% from the prior year.
Not reported for fiscal year 2026.
ELTP Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $141.0M | $148.9M+77.1% | $84.0M+48.4% | $56.6M+65.8% | $34.2M+5.9% | $32.3M+27.1% | $25.4M+41.0% | $18.0M+137.8% | $7.6M+1.5% | $7.5M-22.6% | $9.6M-22.9% | $12.5M+149.2% | $5.0M+9.0% | $4.6M+35.2% | $3.4M+40.4% | $2.4M |
| Cost of Revenue | $79.7M | $73.8M+68.0% | $44.0M+45.2% | $30.3M+72.4% | $17.6M+0.5% | $17.5M+29.3% | $13.5M+34.9% | $10.0M+113.1% | $4.7M+33.9% | $3.5M-40.5% | $5.9M+31.5% | $4.5M+48.8% | $3.0M-6.9% | $3.2M+39.8% | $2.3M+128.4% | $1.0M |
| Gross Profit | $61.3M | $75.0M+87.2% | $40.1M+52.1% | $26.4M+58.8% | $16.6M+12.2% | $14.8M+24.7% | $11.9M+48.7% | $8.0M+178.2% | $2.9M-27.4% | $3.9M+5.6% | $3.7M-53.3% | $8.0M+300.4% | $2.0M+46.6% | $1.4M+25.4% | $1.1M-22.8% | $1.4M |
| R&D Expenses | $6.1M | $5.7M-27.9% | $8.0M+15.7% | $6.9M+11.0% | $6.2M+53.0% | $4.1M-20.8% | $5.1M-7.6% | $5.5M-27.2% | $7.6M-21.0% | $9.6M+15.9% | $8.3M-33.2% | $12.4M-15.6% | $14.7M+272.0% | $4.0M+306.0% | $975K-43.8% | $1.7M |
| SG&A Expenses | $17.7M | $17.6M+95.5% | $9.0M+26.0% | $7.1M+39.5% | $5.1M+14.7% | $4.5M+34.3% | $3.3M-0.8% | $3.3M+8.6% | $3.1M+32.2% | $2.3M+12.0% | $2.1M-28.2% | $2.9M0.0% | $2.9M+37.9% | $2.1M+39.1% | $1.5M+7.3% | $1.4M |
| Operating Income | $34.9M | $49.1M+150.6% | $19.6M+81.7% | $10.8M+193.5% | $3.7M-27.5% | $5.1M+140.9% | $2.1M+192.1% | -$2.3M+75.0% | -$9.2M-1.2% | -$9.1M-23.0% | -$7.4M+11.6% | -$8.3M+49.6% | -$16.5M-212.4% | -$5.3M-238.0% | -$1.6M+20.5% | -$2.0M |
| Interest Expense | $110K | $111K-13.2% | $128K-78.2% | $589K-47.1% | $1.1M+480.1% | $192K-26.1% | $260K-27.1% | $356K-3.6% | $369K+10.0% | $335K+40.8% | $238K-15.1% | $281K-2.3% | $287K-66.6% | $859K+238.7% | $254K+10.5% | $230K |
| Income Tax | $8.4M | $11.9M+180.2% | $4.3M+121.7% | -$19.6M-4733.1% | $424K+124.4% | -$1.7M | N/A | N/A | -$676K+35.4% | -$1.0M+44.0% | -$1.9M-258.8% | -$520K-15918.8% | -$3K+98.9% | -$293K | N/A | N/A |
| Net Income | $56.7M | $44.9M+1140.0% | -$4.3M-121.5% | $20.1M+464.6% | $3.6M-60.0% | $8.9M+74.9% | $5.1M+327.1% | -$2.2M+75.9% | -$9.3M-152.6% | -$3.7M-196.4% | $3.8M+658.0% | -$683K-113.1% | $5.2M+112.7% | -$41.3M-2873.0% | $1.5M+109.9% | -$15.1M |
| EPS (Diluted) | — | $0.03 | $0.00-100.0% | $0.02 | $0.00-100.0% | $0.01 | $0.00 | $0.00+100.0% | -$0.01 | -$0.010.0% | -$0.010.0% | -$0.01+50.0% | -$0.02+90.5% | -$0.21 | $0.00+100.0% | -$0.06 |
TTM is the trailing twelve months, Q2 FY2026 through Q1 FY2027, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ELTP Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $138.3M+43.5% | $96.4M+15.2% | $83.7M+104.6% | $40.9M+16.4% | $35.1M+34.2% | $26.2M+4.9% | $25.0M+2.3% | $24.4M-21.0% | $30.9M-10.0% | $34.3M+8.3% | $31.7M+22.2% | $25.9M+6.6% | $24.3M+118.6% | $11.1M+7.9% | $10.3M |
| Current Assets | $112.1M+94.2% | $57.7M+44.3% | $40.0M+86.0% | $21.5M+14.0% | $18.9M+54.7% | $12.2M+19.0% | $10.3M+15.7% | $8.9M-35.4% | $13.7M-25.6% | $18.4M+10.2% | $16.7M+35.5% | $12.3M+24.2% | $9.9M+290.2% | $2.5M+69.8% | $1.5M |
| Cash & Equivalents | $30.3M+157.2% | $11.8M+65.6% | $7.1M-9.3% | $7.8M-8.2% | $8.5M+167.3% | $3.2M+182.1% | $1.1M-50.3% | $2.3M-68.3% | $7.2M-32.2% | $10.6M-8.0% | $11.5M+54.2% | $7.5M+7.5% | $6.9M+1781.1% | $369K-44.8% | $668K |
| Inventory | $21.3M+30.9% | $16.2M+25.6% | $12.9M+35.4% | $9.6M+41.7% | $6.7M+34.5% | $5.0M+21.0% | $4.1M-8.3% | $4.5M-7.8% | $4.9M-23.7% | $6.4M+94.8% | $3.3M+8.6% | $3.0M+56.9% | $1.9M+42.3% | $1.4M+345.5% | $305K |
| Accounts Receivable | $59.7M+104.5% | $29.2M+50.1% | $19.5M+528.6% | $3.1M+1.2% | $3.1M-12.5% | $3.5M-14.9% | $4.1M+210.7% | $1.3M+95.6% | $676K-27.6% | $934K-39.0% | $1.5M+5.8% | $1.4M+97.6% | $732K+10.1% | $665K+67.6% | $397K |
| Total Liabilities | $39.4M-8.1% | $42.9M+64.4% | $26.1M+118.4% | $11.9M+20.2% | $9.9M-1.1% | $10.0M-29.8% | $14.3M-46.9% | $26.9M+2.3% | $26.3M+204.3% | $8.6M-86.7% | $64.8M+6.8% | $60.7M-42.5% | $105.5M+432.9% | $19.8M-21.7% | $25.3M |
| Current Liabilities | $17.4M+46.9% | $11.8M-9.3% | $13.0M+66.6% | $7.8M+17.0% | $6.7M+15.2% | $5.8M-32.7% | $8.6M+25.1% | $6.9M+35.0% | $5.1M+52.9% | $3.3M-27.9% | $4.6M-8.5% | $5.1M-17.7% | $6.2M+15.0% | $5.4M+17.8% | $4.5M |
| Long-Term Debt | N/A | N/A | N/A | N/A | $1.2M-15.3% | $1.5M-6.7% | $1.6M | N/A | N/A | N/A | N/A | N/A | $19K | N/A | N/A |
| Total Equity | $98.9M+84.8% | $53.5M-7.1% | $57.6M+98.8% | $29.0M+14.8% | $25.2M+56.2% | $16.2M+51.6% | $10.7M+524.9% | -$2.5M-154.9% | $4.6M-82.2% | $25.7M+177.5% | -$33.1M+4.6% | -$34.7M+57.2% | -$81.2M-836.2% | -$8.7M+42.1% | -$15.0M |
| Retained Earnings | -$75.8M+37.2% | -$120.7M-3.7% | -$116.4M+14.7% | -$136.5M+2.5% | -$140.1M+6.0% | -$149.0M+3.3% | -$154.0M-1.5% | -$151.8M-6.5% | -$142.5M-2.6% | -$138.9M+2.7% | -$142.7M-0.5% | -$142.0M+36.9% | -$225.0M-75.2% | -$128.4M+1.1% | -$129.9M |
Not reported in any period shown, so not listed: Goodwill.
ELTP Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $19.0M | $23.7M+218.5% | $7.5M+330.5% | -$3.2M-196.9% | $3.3M-48.7% | $6.5M+103.8% | $3.2M+278.0% | -$1.8M+73.6% | -$6.8M-41.2% | -$4.8M+39.0% | -$7.9M-185.1% | -$2.8M+81.7% | -$15.1M-258.2% | -$4.2M-117.0% | -$1.9M-393.1% | -$394K |
| Capital Expenditures | $1.5M | $926K-43.0% | $1.6M+100.7% | $810K-85.9% | $5.7M+1050.6% | $499K | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | $17.5M | $22.8M+291.4% | $5.8M+244.2% | -$4.0M-68.7% | -$2.4M-139.9% | $6.0M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | -$1.5M | -$926K+61.4% | -$2.4M-196.4% | -$810K+85.9% | -$5.7M-1050.6% | -$499K-89.7% | -$263K-651.8% | -$35K-110.6% | $331K+220.4% | -$275K+75.1% | -$1.1M+43.3% | -$1.9M | N/A | N/A | -$192K+70.8% | -$658K |
| Financing Cash Flow | -$306K | -$4.3M-423.4% | -$826K-124.7% | $3.3M+96.2% | $1.7M+355.2% | -$667K+23.3% | -$870K-226.1% | $690K-56.0% | $1.6M-6.2% | $1.7M-79.3% | $8.1M-7.9% | $8.8M | N/A | N/A | $1.8M+1838.8% | -$106K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q2 FY2026 through Q1 FY2027, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ELTP Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 50.4%+2.7pp | 47.7%+1.1pp | 46.6%-2.0pp | 48.6%+2.7pp | 45.9%-0.9pp | 46.8%+2.4pp | 44.3%+6.5pp | 37.9%-15.0pp | 52.9%+14.1pp | 38.8%-25.3pp | 64.1%+24.2pp | 39.9%+10.2pp | 29.7%-2.3pp | 32.0%-26.2pp | 58.2% |
| Operating Margin | 33.0%+9.7pp | 23.3%+4.3pp | 19.1%+8.3pp | 10.8%-5.0pp | 15.7%+7.4pp | 8.3%+21.0pp | -12.7% | -121.0% | -121.4% | -76.3%-9.8pp | -66.5% | -329.1% | -114.8% | -45.9%+35.2pp | -81.1% |
| Net Margin | 30.1%+35.3pp | -5.1%-40.6pp | 35.5%+25.1pp | 10.4%-17.1pp | 27.6%+7.5pp | 20.1%+32.5pp | -12.4% | -122.6% | -49.3%-88.8pp | 39.5%+45.0pp | -5.5% | 104.1% | -896.7% | 43.7% | -621.2% |
| Return on Equity | 45.4%+53.4pp | -8.1%-43.0pp | 34.9%+22.6pp | 12.3%-23.0pp | 35.3%+3.8pp | 31.5%+52.5pp | -21.0% | N/A | -80.3%-95.2pp | 14.8% | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | 32.5%+36.9pp | -4.5%-28.5pp | 24.0%+15.3pp | 8.7%-16.6pp | 25.3%+5.9pp | 19.4%+28.4pp | -9.0%+29.1pp | -38.0%-26.1pp | -11.9%-23.0pp | 11.1%+13.3pp | -2.2%-22.3pp | 20.1%+189.8pp | -169.7%-183.0pp | 13.4%+159.4pp | -146.0% |
| Current Ratio | 6.45+1.6x | 4.88+1.8x | 3.07+0.3x | 2.75-0.1x | 2.82+0.7x | 2.10+0.9x | 1.19-0.1x | 1.28-1.4x | 2.68-2.8x | 5.50+1.9x | 3.60+1.2x | 2.43+0.8x | 1.61+1.1x | 0.47+0.1x | 0.33 |
| Debt-to-Equity | 0.40-0.4x | 0.80+0.3x | 0.450.0x | 0.41+0.4x | 0.050.0x | 0.09-0.1x | 0.15 | N/A | 5.76+5.4x | 0.34 | N/A | N/A | N/A | N/A | N/A |
| FCF Margin | 15.3%+8.4pp | 6.9%+14.1pp | -7.1%-0.1pp | -7.0%-25.7pp | 18.6% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Where Elite Pharmaceuticals Inc Ranks
Frequently Asked Questions
What is Elite Pharmaceuticals Inc's annual revenue?
Elite Pharmaceuticals Inc (ELTP) reported $148.9M in total revenue for fiscal year 2026. This represents a 77.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Elite Pharmaceuticals Inc's revenue growing?
Elite Pharmaceuticals Inc (ELTP) revenue grew by 77.1% year-over-year, from $84.0M to $148.9M in fiscal year 2026.
Is Elite Pharmaceuticals Inc profitable?
Yes, Elite Pharmaceuticals Inc (ELTP) reported a net income of $44.9M in fiscal year 2026, with a net profit margin of 30.1%.
What is Elite Pharmaceuticals Inc's EBITDA?
Elite Pharmaceuticals Inc (ELTP) had EBITDA of $50.2M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
What is Elite Pharmaceuticals Inc's gross margin?
Elite Pharmaceuticals Inc (ELTP) had a gross margin of 50.4% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.
What is Elite Pharmaceuticals Inc's operating margin?
Elite Pharmaceuticals Inc (ELTP) had an operating margin of 33.0% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.
What is Elite Pharmaceuticals Inc's net profit margin?
Elite Pharmaceuticals Inc (ELTP) had a net profit margin of 30.1% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.
What is Elite Pharmaceuticals Inc's return on equity (ROE)?
Elite Pharmaceuticals Inc (ELTP) has a return on equity of 45.4% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is Elite Pharmaceuticals Inc's free cash flow?
Elite Pharmaceuticals Inc (ELTP) generated $22.8M in free cash flow during fiscal year 2026. This represents a 291.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Elite Pharmaceuticals Inc's operating cash flow?
Elite Pharmaceuticals Inc (ELTP) generated $23.7M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.
What are Elite Pharmaceuticals Inc's total assets?
Elite Pharmaceuticals Inc (ELTP) had $138.3M in total assets as of fiscal year 2026, including both current and long-term assets.
What are Elite Pharmaceuticals Inc's capital expenditures?
Elite Pharmaceuticals Inc (ELTP) invested $926K in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
How much does Elite Pharmaceuticals Inc spend on research and development?
Elite Pharmaceuticals Inc (ELTP) invested $5.7M in research and development during fiscal year 2026.
What is Elite Pharmaceuticals Inc's current ratio?
Elite Pharmaceuticals Inc (ELTP) had a current ratio of 6.45 as of fiscal year 2026, which is generally considered healthy.
What is Elite Pharmaceuticals Inc's debt-to-equity ratio?
Elite Pharmaceuticals Inc (ELTP) had a debt-to-equity ratio of 0.40 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Elite Pharmaceuticals Inc's return on assets (ROA)?
Elite Pharmaceuticals Inc (ELTP) had a return on assets of 32.5% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is Elite Pharmaceuticals Inc's Altman Z-Score?
Elite Pharmaceuticals Inc (ELTP) has an Altman Z-Score of 6.98, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Elite Pharmaceuticals Inc's Piotroski F-Score?
Elite Pharmaceuticals Inc (ELTP) has a Piotroski F-Score of 6 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Elite Pharmaceuticals Inc's earnings high quality?
Elite Pharmaceuticals Inc (ELTP) has an earnings quality ratio of 0.53x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Elite Pharmaceuticals Inc cover its interest payments?
Elite Pharmaceuticals Inc (ELTP) has an interest coverage ratio of 441.03x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.